MNM Bioscience Inc. Company

MNM has built a technology to rank cancer treatment based on molecular features of a tumor sample. AI heavy, the software analyses 100% of tumor genomic information (traditionally <0.1% is used) and by extracting “biomarker signatures” from individual tumor, matches it with the collection of biomarker signatures developed for each individual therapies. It results in a ranking of most likely effective cancer therapies. The technology also allows for novel target identification.
Technology: Artificial Intelligence, Biotechnology, Genetics, Health Diagnostics, Software
Industry: Data Processing
Headquarters: Cambridge, Massachusetts, United States
Founded Date: 2018-03-01
Employees Number: 11-50
Funding Status: Seed
Investors Number: 2
Total Funding: 2614000
Last Funding Date: 2021-06-20
Last Funding Type: Seed

Visit Website
contact@mnm.bio
https://twitter.com/BioscienceMnm
Register and Claim Ownership